Clinical Trials Logo
  1. Home
  2. IMAGE
  3. NCT04498611

Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy

Invasive Breast Cancer Clinical Trial

Official title:
Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy: A Development and Validation Study

Clinical Trial Summary

It is considered that whether or not the accompanying invasive cancer classified through MRI images of breast cancer patients identified as Ductal Carcinoma in situ (DCIS) through preoperative tissue biopsy is significantly consistent with the postoperative stage. Therefore, this study intend to evaluate the effectiveness as a diagnostic tool that can help determine the axillary lymph node surgery by predicting the possibility of post-operative up-staging using magnetic resonance imagings of breast cancer patients who have been identified as ductal carcinoma in situ and are scheduled for surgery.

Clinical Trial Description

1. To date, there is no significant research data on the value of the Apparent Diffusion Coefficient (ADC) that can distinguish between pure Ductal Carcinoma in situ (pure DCIS) and invasive cancer (DCIS-IC), from June 2019 to 2020 1 Of the 144 patients who obtained Diffusion Weighted images (b=0,800,1200) with 3.0-T MRI equipment and diagnosed with ductal carcinoma in situ on the biopsy, among 144 patients who did not undergo preoperative chemotherapy using a CAD program, the 3-dimensional Apparent Diffusion Coefficient value of the tumor is measured and compared with whether or not there is invasive cancer after surgery, and the optimal Apparent Diffusion Coefficient reference value that can predict the invasive cancer will be retrospectively derived. 2. Scheduled MRI tests will be performed on patients enrolled from July 2020, and will be performed using the standard protocols (3T, contrast enhancement and diffuse enhancement images DWI b0,800,1200). Among the MRI images taken, the range of lesions is evaluated in contrast-enhanced T1-highlighted images, and the Apparent Diffusion Coefficient values of the lesions are three-dimensionally mapped using a CAD program and histogram analysis on diffused images. The ADC reference value derived from the retrospective analysis is used to predict prospectively for invasive cancer in all lesions. 3. Mastectomy is performed according to the existing surgical method. Axillary lymph node surgery is determined according to the existing decision method (tumor location, size, range, histological grade, etc.). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04498611
Study type Interventional
Source Seoul National University Hospital
Contact
Status Completed
Phase N/A
Start date July 13, 2020
Completion date August 15, 2021
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03595592 - Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer Phase 3
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT06158217 - Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT02773784 - Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
Recruiting NCT01509781 - Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Phase 3
Completed NCT04478669 - Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer
Recruiting NCT04553770 - Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Phase 2
Recruiting NCT04677816 - Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Phase 2
Terminated NCT01934335 - Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer Phase 2
Completed NCT00507611 - Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients N/A
Completed NCT00581750 - Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
Completed NCT03304171 - Overall Diet Quality and Breast Cancer Risk N/A
Completed NCT03709186 - Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
Terminated NCT03361800 - Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC Early Phase 1
Recruiting NCT04648904 - Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer Early Phase 1
Recruiting NCT06328465 - fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases N/A
Active, not recruiting NCT03109522 - Axillary Reverse Mapping (ARM) Technique N/A
Recruiting NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Recruiting NCT03497702 - Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer Phase 2